Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.
Journal: Clinical and translational science
Published: October 21, 2020
Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.
Journal: JMIR research protocols
Published: October 12, 2019
Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.
Journal: Arthritis research & therapy
Published: June 26, 2019
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.
Journal: Clinical pharmacology and therapeutics
Published: August 17, 2018
Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Journal: Pharmacology research & perspectives
Published: October 11, 2017
Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C.
Journal: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
Published: September 17, 2015
Pegylated interferons Lambda-1a and alfa-2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells.
Journal: Journal of viral hepatitis
Published: May 16, 2014
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates.
Journal: Journal of clinical pharmacology
Published: February 24, 2014
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables.
Journal: Journal of clinical pharmacology
Published: February 24, 2014
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
Journal: Journal of hepatology
Published: January 20, 2014
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic.
Journal: Journal of clinical and translational hepatology
Published: August 30, 2013
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: May 16, 2013
Last Updated: 09/26/2026